secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001104659-25-017178
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics passes Phase 2 futility analysis for zervimesine in geographic atrophy
--------------------------------------------------------------------------------

- Oral zervimesine (CT1812) passed futility analysis in Phase 2 GA trial; treated patients experienced slower lesion growth vs placebo.
- MAGNIFY study enrolled 100 participants; final visits completed Feb 2025; full unblinded results expected Q2 2025.
- Company concluding study early to preserve capital; plans to pursue indications in Alzheimer's and DLB.
- Prior Phase 2 SHIMMER (DLB) showed 86% improvement on NPI; SHINE (Alzheimer's) showed 95% cognitive decline reduction in biomarker subgroup.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925017178/0001104659-25-017178-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465925017178/tm257579d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-017178

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer